RxDoctor Payments Data

Kathryn Lawson, DO

Rheumatology · Jacksonville, FLNPI 1609962679

Payments from drug & device makers

$1,414in general payments, 2019–2025

Across 79 payments — averaging $17.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$518
  • Johnson & Johnson$147
  • Genentech USA, Inc.$117
  • UCB, Inc.$86
  • AstraZeneca$83
  • E.r. Squibb & Sons, L.L.C.$69
  • plus $395 from 13 others

What the payments were for

  • Food & beverage$1,414100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,414 in reported general payments places this provider in the 20th percentile of 453 rheumatology providers in Florida.

See all rheumatology providers in Florida

Medicare billing

Part B allowed, 2024
$16,416
Medicare patients
83
Services billed
129

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept29$209,172
Humira(Cf) PenAdalimumab20$174,491
Xeljanz XrTofacitinib Citrate20$114,858
XeljanzTofacitinib Citrate12$67,337
Hydroxychloroquine Sulfate125$5,575
MethotrexateMethotrexate Sodium169$4,058
Leflunomide30$3,347
Prednisone179$1,566
Allopurinol48$716
Azathioprine11$488
Folic Acid35$356
Methylprednisolone20$190
Alendronate Sodium16$151
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim13$110

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerXeljanz$15$67,33712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 453 rheumatology providers in Florida.

Other rheumatology in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →